Agreement Between Color, Fluorescein Angiography, and Spectral Domain Optical Coherence Tomography in the Detection of Macular Fibrosis in Neovascular Age-Related Macular Degeneration - 18/03/25

HIGHLIGHTS |
• | Optical coherence tomography (OCT) is superior to color imaging and fluorescein angiography (FA) for detecting fibrosis. |
• | Detection sensitivity of fibrosis on color or FA varies with hyperreflective material location. |
• | OCT-detected hyperreflective material explains visual acuity variance in neovascular age-related macular degeneration (AMD). |
Résumé |
Purpose |
To evaluate the agreement between fibrosis on color imaging–, fluorescein angiography (FA)–, and spectral domain optical coherence tomography (SD-OCT)–detected hyperreflective material (HRM) and assess their clinical relevance.
Design |
Clinical cohort and diagnostic accuracy study.
Methods |
Multimodal fundus images (color, FA, and SD-OCT) of 130 eyes with neovascular age-related macular degeneration, collected 18 months after the initiation of anti–vascular endothelial growth factor treatment (anti-VEGF) as part of the Early Detection of Neovascular AMD (EDNA) study, were regraded for fibrosis and HRM. HRM location was assigned as subretinal (SR) and/or subretinal pigment epithelial (SPE). Agreement between detection methods was assessed with the kappa statistic, and regression analysis with best corrected visual acuity (BCVA) as outcome variable was used to evaluate clinical relevance.
Results |
Kappa was 0.56 for FA and 0.40 for HRM on SD-OCT, using color as the reference. Regression against BCVA showed low R² values for all tests (R² < 0.09). In the HRM-OCT model, with no HRM as the reference and location and dimensions as covariates, the R² increased to 0.301. Letter loss was 21.1 (P < .0001) for SR and 8.1 (P = .045) for SPE. When HRM on SD-OCT was the reference, the sensitivity for color and FA combination was 87.5% but was lower at 33.3% for SPE only.
Conclusions |
Well-defined HRM detected by SD-OCT during the maintenance phase of anti-VEGF therapy explains BCVA variance, positioning OCT as a superior standard for detecting fibrosis.
Le texte complet de cet article est disponible en PDF.Plan
| Supplemental Material available at AJO.com. |
|
| Meeting Presentation: Parts of the data in the manuscript were previously presented at the Cole Eye Institute Imaging Summit during ASRS Stockholm, Sweden, July 2024, and at the World Sight Day 2024, Belfast, United Kingdom, October 2024. |
Vol 272
P. 126-135 - avril 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
